Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2011009020) COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2011/009020 International Application No.: PCT/US2010/042218
Publication Date: 20.01.2011 International Filing Date: 16.07.2010
Chapter 2 Demand Filed: 16.05.2011
IPC:
A61K 31/485 (2006.01) ,A61P 35/00 (2006.01) ,A61K 45/06 (2006.01) ,A61K 31/472 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
485
Morphinan derivatives, e.g. morphine, codeine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
472
Non-condensed isoquinolines, e.g. papaverine
Applicants:
MALLINCKRODT LLC [US/US]; 675 McDonnell Boulevard Hazelwood, Missouri 63042, US (AllExceptUS)
CANTRELL, Gary, L. [US/US]; US (UsOnly)
BERBERICH, David, W. [US/US]; US (UsOnly)
RAJAGOPALAN, Raghavan [US/US]; US (UsOnly)
KARWA, Amolkumar [IN/US]; US (UsOnly)
DORSHOW, Richard, B. [US/US]; US (UsOnly)
Inventors:
CANTRELL, Gary, L.; US
BERBERICH, David, W.; US
RAJAGOPALAN, Raghavan; US
KARWA, Amolkumar; US
DORSHOW, Richard, B.; US
Agent:
SEURER, Jerad, G.; Mallinckrodt LLC 675 McDonnell Boulevard Hazelwood, Missouri 63042, US
Priority Data:
61/226,01516.07.2009US
61/226,03216.07.2009US
61/238,35831.08.2009US
61/286,87716.12.2009US
Title (EN) COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS
(FR) COMPOSÉS ET COMPOSITIONS POUR UNE UTILISATION EN PHOTOTHÉRAPIE ET DANS LE TRAITEMENT D'UNE MALADIE NÉOVASCULAIRE OCULAIRE ET DE CANCERS
Abstract:
(EN) The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
(FR) L'invention porte d'une manière générale sur des agents anti-angiogenèse et sur des procédés apparentés d'utilisation d'agents anti-angiogenèse pour des applications biomédicales comprenant une monothérapie directe et une thérapie de combinaison pour le traitement d'un état lié à l'angiogenèse. Dans un mode de réalisation, l'invention porte sur une classe de composés opioïdes et de dérivés opioïdes structuralement apparentés présentant une activité anti-VEGF pour une utilisation dans des actes thérapeutiques, comprenant une photothérapie. Les composés opioïdes et les dérivés opioïdes structuralement apparentés de l'invention peuvent être administrés seuls ou en combinaison avec l'administration d'un agent de photothérapie et/ou d'autres agents thérapeutiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)